Discover open access scientific publications

Search, annotate, share and cite publications

Publications by X. Zhang

P2.12-17 Prophylactic Cranial Irradiation Can Not Provide Survival Benefits for Resected Small Cell Lung Cancer Without Lymph Node Involvement

Journal of Thoracic Oncology

English

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

Journal of Thoracic Oncology

English

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

Journal of Thoracic Oncology

English

P3.01-01 Prospective Comparison of Four Plasma Testing Platforms for T790M and Effectiveness of Osimertinib in Chinese NSCLC Patients

Journal of Thoracic Oncology

English

P103 Genomic Evolution Analysis Delineates Acquisition of Invasiveness in Pathological Subtypes of Early-Stage Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P009 to Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC With Wild-Type EGFR

Journal of Thoracic Oncology

English

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients With Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Journal of Thoracic Oncology

English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology

English

P1.11-19 Expression of TNFRII in Serum Is Correlated With the Significant Risk of Subcentimeter Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P092 Apatinib Reverses Paclitaxel Resistance in Lung Cancer

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by X. Zhang

P2.12-17 Prophylactic Cranial Irradiation Can Not Provide Survival Benefits for Resected Small Cell Lung Cancer Without Lymph Node Involvement

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

P3.01-01 Prospective Comparison of Four Plasma Testing Platforms for T790M and Effectiveness of Osimertinib in Chinese NSCLC Patients

P103 Genomic Evolution Analysis Delineates Acquisition of Invasiveness in Pathological Subtypes of Early-Stage Lung Adenocarcinoma

P009 to Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC With Wild-Type EGFR

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients With Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

P1.11-19 Expression of TNFRII in Serum Is Correlated With the Significant Risk of Subcentimeter Lung Adenocarcinoma

P092 Apatinib Reverses Paclitaxel Resistance in Lung Cancer